Characterization of Atg38 and NRBF2, a fifth subunit of the autophagic Vps34/PIK3C3 complex

Yohei Ohashi, Nicolas Soler, Miguel García Ortegón, Lufei Zhang, Marie L. Kirsten, Olga Perisic, Glenn R. Masson, John E. Burke, Arjen J. Jakobi, Apostolos A. Apostolakis, Christopher M. Johnson, Maki Ohashi, Nicholas T. Ktistakis, Carsten Sachse, and Roger L. Williams

MRC Laboratory of Molecular Biology, Cambridge, United Kingdom; European Molecular Biology Laboratory, Structural and Computational Biology Unit, Heidelberg, Germany; European Molecular Biology Laboratory, Hamburg Unit, Hamburg, Germany; The Babraham Institute, Cambridge, UK

Introduction

Vps34, the primordial phosphatidylinositol 3-kinase (PtdIns3K) that phosphorylates the 3-OH of phosphatidylinositol to form phosphatidylinositol 3-phosphate (PtdIns3P), is conserved in all eukaryotes, and it is important for endocytic traffic to lysosomes and vacuoles and for autophagy. PtdIns3P, which is targeted by PtdIns3P-binding proteins such as Atg18 (WIPI1/2/3/4 in mammalian cells), is essential for autophagosome creation. A fifth subunit of complex I, Atg38, has been described in yeast, and in vivo experiments suggested that this recently discovered subunit is important for the integrity of complex I. Araki et al. postulate that Atg38 is orthologous to NRBF2 in mammals, and 3 recent studies in mammalian cells support this proposition. All studies agree that Atg38/NRBF2 binds to complex I, and that this subunit localizes to phagophores during starvation. However, there are several discrepancies among the reported results. Lu et al. show that NRBF2 binds to both complex I and complex II, whereas others have shown that Atg38/NRBF2 is complex I-specific. It has been reported that NRBF2 is critical for induction of autophagy, while one report indicates that NRBF2 suppresses autophagy. Also, each study identifies different components of complex I as binding partners of Atg38/NRBF2. Araki et al. show that Atg38 binds to Atg14 and Vps34, while another study reports NRBF2 binds to the WD40 domain of Vps15, but not to either BECN1 or ATG14. Other reports show NRBF2 binds to ATG14. These ambiguities might have been caused by

ABSTRACT

The phosphatidylinositol 3-kinase Vps34 is part of several protein complexes. The structural organization of heterotetrameric complexes is starting to emerge, but little is known about organization of additional accessory subunits that interact with these assemblies. Combining hydrogen-deuterium exchange mass spectrometry (HDX-MS), X-ray crystallography and electron microscopy (EM), we have characterized Atg38 and its human ortholog NRBF2, accessory components of complex I consisting of Vps15-Vps34-Vps30/Atg6-Atg14 (yeast) and PIK3R4/PIK3C3/PIK3C3-VPS34-BECN1/Becn1-ATG14 (human). HDX-MS shows that Atg38 binds the Vps30-Atg34 subcomplex of complex I, using mainly its N-terminal MIT domain and its human ortholog NRBF2, accessory components of complex I consisting of Vps15-Vps34-Vps30/Atg6-Atg14 (yeast) and PIK3R4/PIK3C3/PIK3C3-VPS34-BECN1/Becn1-ATG14 (human). HDX-MS shows that Atg38 binds the Vps30-Atg34 subcomplex of complex I, using mainly its N-terminal MIT domain and homodimerization. Our 2.2 A resolution crystal structure of the Atg38 C-terminal homodimerization domain shows 2 segments of α-helices assembling into a mushroom-like asymmetric homodimer with a 4-helix cap and a parallel coiled-coil stalk. One Atg38 homodimer engages a single complex I. This is in sharp contrast to human NRBF2, which also forms a homodimer, but this homodimer can bridge 2 complex I assemblies.
employing different experimental systems and using immuno-precipitates rather than purified proteins.

The domain organization of Atg38 and NRBF2 sheds some light on how these proteins might function. Both Atg38 and NRBF2 have an N-terminal microtubule-interacting and targeting (MIT) domain and a C-terminal region of unknown structure. The MIT domain of Atg38 and NRBF2 is important for binding to complex I and for functionality during starvation. Compared to the MIT domain, the function of the C-terminal region remains unclear except that it has a role in homodimerization.

In order to clarify how Atg38 and NRBF2 interact with complex I and to understand the consequences of these interactions, we compared the structural organization of complex I in the presence and absence of Atg38/NRBF2. We find that stable yeast and human complex I can be purified both in the presence and absence of Atg38/NRBF2. Using hydrogen-deuterium exchange mass-spectrometry (HDX-MS), we mapped interactions between the MIT domain of Atg38 and the coiled-coil regions of Atg14 and Vps30 in the Atg14-Vps30 arm of complex I. The second arm of complexes I and II, consisting of the common Vps15-Vps34 core, does not appear to directly interact with Atg38 in complex I. Moreover, we determined the 2.2 Å resolution crystal structure of the C-terminal region of Atg38, revealing a homodimeric α-helical structure with a 4-helix bundle on top of an asymmetric coiled-coil stalk. In vivo experiments suggest that this C-terminal region is important for homodimerization, binding to complex I, localization to the PAS and potential membrane interaction. We also show that the yeast Atg38 and human NRBF2 homodimers have striking differences in their abilities to dimerize complex I.

Results

Yeast Vps15, Vps34, Vps30 and Atg14 form a 1:1:1:1 heterotetramer that interacts with Atg38

To gain insight into the organization and function of Vps34 complexes, we coexpressed the core 4 subunits of S. cerevisiae complex I in yeast. The purified complex shows stoichiometric ratios of the 4 components by SDS-PAGE analysis. Size exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) shows a monodisperse peak with molecular mass of 390 kDa consistent with a 1:1:1:1 complex (expected mass is 379 kDa and calibration of the SEC-MALS with known standards indicates an error of less than 5%) (Fig. 1A).

To examine the interaction of Atg38 with complex I, we first purified Atg38 on its own. SEC-MALS analysis of purified Atg38 reveals a monodisperse peak with a molecular mass of 51.4 kDa (Fig. 1B). Given a monomeric mass of 26 kDa for Atg38, this suggests that the protein forms a homodimer. We then mixed purified heterotetrameric complex I with a 6-fold excess of purified Atg38 and analyzed the mixture by gel filtration. Atg38 was clearly incorporated into the complex I peak as shown by SDS PAGE analysis of the gel filtration fractions and was clearly separated from the free Atg38 peak (Fig. 1C). The gel-filtration purified heterotetrameric complex I was then analyzed by SEC-MALS. This analysis shows a monodisperse peak with a molecular mass of 425 kDa (Fig. 1D), suggesting that one homodimer of Atg38 binds to one heterotetrameric complex I (expected mass of 431 kDa).

Given that an Atg38 homodimer can interact with one complex I, we asked whether this stoichiometry was simply a consequence of reconstitution with an excess of Atg38 or whether this stoichiometry is maintained independently of the reconstitution conditions. Regardless of whether we use 6-fold molar excess complex I or 6-fold excess of Atg38, our gel filtration analysis shows only one peak containing both complex I and Atg38 (Fig. S1). SDS PAGE analysis of the gel filtration peak of the heteropentamer formed by mixing complex I with a 6-fold molar excess of Atg38 indicates a stoichiometry of 1:1:1:1:2 (Fig. 1C and S1), consistent with the SEC-MALS analysis shown in Fig. 1D. When the heteropentamer is reconstituted in a condition with a 6-fold molar excess of complex I compared with Atg38, the SDS PAGE is consistent with a mixture of predominantly heterotetrameric complex I and a minor population of heteropentamer (Fig. S1). Since there is no evidence of a larger complex induced by Atg38, these results indicate that Atg38 homodimers preferentially interact with only one complex I and do not link 2 heterotetramers.

Interaction of human complex I with NRBF2

In order to better understand the role of the human ortholog of Atg38, NRBF2, in the context of the human complex I, we transiently expressed and purified the corresponding heterotetrameric complex in HEK293T cells (Fig. 2). SDS PAGE reveals that the purified complex contains all expected components at stoichiometric ratios (Fig. 2A, lane T). SEC-MALS indicates that free NRBF2 has a mass of 67 kDa (Fig. 2B), confirming that the 32.5 kDa NRBF2 forms a homodimer, analogous to Atg38. We tested the incorporation of NRBF2 into the heterotetrameric human complex I both by expressing all 5 components together in HEK293T cells or by adding purified NRBF2 to HEK293T lysates expressing the heterotetrameric complex. SDS PAGE shows that NRBF2 incorporates efficiently into the human heterotetrameric complex either when coexpressed (Fig. 2A) or when reconstituted (Fig. 2C). Glycerol gradient ultracentrifugation of both the heterotetrameric and heteropentameric complexes showed that most of the material migrates in the same density of approximately 25% glycerol (Fig. 2D).

We asked whether the size of the human heteropentamer is influenced by the relative abundance of NRBF2. When a 6-fold molar excess of complex I is mixed with NRBF2, SEC-MALS shows only 2 peaks (Fig. S2, blue trace). The first peak (fractions 2 and 3), with larger mass than complex I alone, has an average mass most consistent with 2 complexes linked by an NRBF2 dimer, and the second peak (in fractions 7 and 8) appears to consist of complex I alone. In contrast, when a 6-fold molar excess of NRBF2 is mixed with human complex I and analyzed by SEC-MALS, 2 new higher mass peaks appear compared with individual components alone (red trace Fig. S2). The first peak (in fractions 2 and 3, Fig. S2) with the largest mass is most consistent with 2 heterotetrameric complexes linked by an NRBF2 homodimer. The second peak (fraction 5, Fig. S2) shows a mass of 481 kDa, which is closest to the expected mass of one complex I with one NRBF2 homodimer (calculated mass 437 kDa). The fourth peak consisting of NRBF2 dimer alone (Fraction 11) is well separated from the
heteromeric complexes. These results suggest that in contrast to yeast Atg38, one NRBF2 homodimer can bridge 2 copies of human complex I. Although the MIT domain of NRBF2 interacts with complex I, the MIT domain on its own cannot bridge 2 complexes. When human complex I was mixed with NRBF2 MIT domain (ratio of 6 complex I:1 MIT) and analyzed by gel filtration (Fig. S3), the complex I-MIT mixture eluted as a single peak at nearly the same volume as complex I alone. SDS PAGE analysis of the peak shows all 5 components. This shows that the monomeric MIT domain cannot link 2 complex I assemblies.

Using negative staining EM analysis of GraFix\textsuperscript{12} cross-linked heterotetrameric and heteropentameric human complexes (Fig. 2E), we examined the homogeneous fractions. This material consists of predominantly single asymmetric assemblies (Fig. S4) with an overall V-shape as reported previously.\textsuperscript{13} Additional density visible at the base of the V in some class averages suggests interaction of NRBF2 with the heterotetrameric complex (Fig. 2E).

**Mapping the Atg38-complex I interface by HDX-MS**

We mapped the binding between the yeast complex I and Atg38 using hydrogen-deuterium exchange mass-spectrometry (HDX-MS), which provides information related to solvent accessibility for protein backbone amide hydrogens. This technique enables mapping of protein-protein interactions in solution without requiring any labeling, mutagenesis or truncation variants.\textsuperscript{14,15} We determined HDX for 3 entities: the heterotetrameric complex I (Vps15-Vps34-Vps30-Atg14), free Atg38 and complex I with Atg38 (the heteropentamer was reconstituted in the presence of excess Atg38 and gel filtered; the peak with complex I bound to Atg38 was concentrated and used for HDX-MS). Differences in HDX among these states provide information related to their relative accessibilities (Fig. 3). In Atg38, the 3 predicted helices of the N-terminal MIT-like domain were highly protected from exchange in the presence of complex I, suggesting that this region participates in binding to complex I (Fig. 3A). This is consistent with analysis of Atg38 deletion variants showing that the minimal construct that binds complex I is the MIT domain alone (residues 1 to 78, Fig. 3F).

Two regions in the C-terminal domain of Atg38 are also more protected from exchange in the presence of complex I (Fig. 3A). Although this domain could directly bind complex I, GST affinity isolation assays indicate that the C-terminal region alone (residues 87 to 226) is not sufficient for in vitro binding (Fig. 3F). Alternatively, since the C-terminal domain of Atg38 is important for forming a homodimer, the dimeric Atg38 binding to complex I could rigidify the C-terminal region,
leading to decreased exchange. It may be that dimeric Atg38 increases avidity of the interaction for complex I, and that the C-terminal region is important for this dimeric avidity, but this role for the C-terminal domain would be masked in the GST affinity isolation analysis, since GST itself can form dimers.16 Atg14 contains 3 coiled-coil motifs (coil I, II, and III).17 We found that coiled-coil I (residues 25 to 36) was highly protected in the presence of Atg38 (Fig. 3B), suggesting that this region of Atg14 interacts with Atg38. We also found that the coiled-coil II of Vps30 (residues 188 to 2107) was protected in the presence of Atg38 (Fig. 3C). Because it is known that coiled-coil II of Atg14 binds the coiled-coil of Vps30,17 this change in HDX for Vps30 could be due either to a direct interaction with Atg38 or it may reflect Atg38 reinforcing the interaction between Vps30 and Atg14. Besides protections, several regions become more exposed in the presence of Atg38: the coiled-coil III of Atg14 (Fig. 3B), the last half of coiled-coil II of Vps30 (Fig. 3C) and several regions in the WD40 domain of Vps15 (Fig. 3D; residues 1076 to 1112, 1352 to 1363, 1406 to 1429, and 1442 to 1449). Based on the crystal structure of yeast complex II7 and the 28 Å resolution negative-stain EM structure of human complex I,13 these regions map to a single area in complex I, which may undergo some conformational rearrangements within complex I upon Atg38 binding. Although it was reported that Atg38 binds Vps34 based on yeast 2-hybrid analysis,8 we found no significant differences in HDX in Vps34 (Fig. 3E). The Vps34 interaction detected in the 2-hybrid analysis might not have been a direct interaction. However, we do not exclude the possibility that the regions of Vps34-Vps15 for which we have no coverage in the HDX-MS analysis (10% of the residues in Vps34 and 40% in Vps15) may contribute to interaction with Atg38. We determined a 28-A resolution structure of the isolated Vps15-Vps34 heterodimer (Fig. S5), which suggests that the structure of this heterodimeric core is similar to what is observed in complex II thatdoes not bind Atg38.

Crystal structure of the C-terminal homodimerization region of Atg38

To gain insight into the role of the C-terminal region of Atg38, we determined its structure by X-ray crystallography. We obtained crystals using full-length Atg38 S. cerevisiae protein that had been subjected to limited proteolysis with subtilisin. The structure was solved by multiwavelength anomalous dispersion (MAD) using selenomethionine-
derivatized protein and was refined to 2.2 Å resolution (Table 1). The structure showed that the crystallized region corresponds to residues 119 to 211 in the Atg38 C-terminal domain.

The asymmetric unit has 3 copies of an Atg38 homodimer (Fig. 4A). The 3 homodimers in the asymmetric unit are related by a 3-fold non-crystallographic rotational axis that is approximately parallel to the b axis of the unit cell. Because each of the
The other monomer is bent at residue F182 at an angle of 211. Each homodimer is strikingly asymmetric with the entire helical, with a short N-terminal helix A (residues 129 to 211). 3 copies of the homodimer are very similar, and because the contacts within the cap. In the cap, residues L130 to D145 and 2 salt bridges. The asymmetry of the dimer is manifest in the hydrophobic contacts. For example, the center of the cap, residues F170 and L174 in the straight helix B contact the corresponding residues of the kinked helix B (Fig. 4B, lower panel). F170 also contacts L135 in helix A. However, the asymmetry of the cap means that other aspects of the environment of L135 are different for the 2 molecules. This asymmetry of the homodimerization disappears in the stalk (Fig. 4C).

To estimate the overall flexibility of Atg38, we used HDX-MS to measure the global exchange of the isolated Atg38 subunit. In order to map the HDX-MS results on the structure, we combined a homology model for the Atg38 N-terminal MIT domain based on the N-terminal MIT domain of NRBF2 (PDB entry 2CRB), with the crystal structure of the C-terminal domain (Fig. 4D). The HDX heat map clearly shows that the linker between these domains is disordered (warm colors, Fig. 4D). Conversely, the middle region of the MIT domain, the bottom half of the cap segment, and the residues 195 to 205 of the stalk were protected. HDX-MS shows that as with the N-terminal MIT domain, the C-terminal domain of Atg38 becomes protected upon incorporation into complex I (Fig. 3A), probably due to stabilization of the subunit and possibly due to direct interactions with complex I.

| Table 1. Data collection, phasing and refinement statistics. |
|---------------------------------------------------------------|
| **Data collection** | Native (MGOx11) | SeMet (MGOx65) |
| **Space group** | P2₁2₁2 | P2₁2₁2 |
| **Cell dimensions** | a, b, c (Å) | 81.38, 249.28, 50.20 | 81.27, 249.95, 50.28 |
| **α, β, γ (°)** | 90, 90, 90 | 90, 90, 90 |
| **Wavelength** | 0.979320 | 0.979320 |
| **Resolution (Å)** | 2.2 (2.27–2.2) | 2.2 (2.6–2.5) |
| **Rmerge or Rrmerge** | 0.062 (0.891) | 0.11 (1.39) |
| **I/σI** | 16.9 (2.3) | 16.1 (2.2) |
| **Completeness (%)** | 99.8 (99.6) | 99.7 (99.7) |
| **Redundancy** | 6.6 (6.3) | 13.0 (13.8) |
| **Refinement** | Resolution (Å) | 2.2 |
| **No. reflections** | 52821 |
| **Rwork / Rfree** | 0.20 / 0.24 |
| **No. atoms** | Protein | 4380 |
| **Ligand/ion** | 144 |
| **Water** | 43 |
| **β-factors (Å²)** | Protein | 84.03 |
| **Ligand/ion** | 79.37 |
| **Water** | 58.38 |
| **R.m.s deviations** | Bond lengths (Å) | 0.0054 |
| **Bond angles (°)** | 0.769 |

*Numbers in parentheses represent statistics for the highest resolution shell.*

3 copies of the homodimer are very similar, and because the molecule is a homodimer in solution, our description will refer to a single homodimer. The ordered parts of the monomers are entirely helical, with a short N-terminal helix A (residues 129 to 150) folded back over a part of a longer helix B (residues 164 to 211). Each homodimer is strikingly asymmetric with the long helix B in one monomer almost straight, while helix B in the other monomer is bent at residue F182 at an angle of 211°. The turn between helices A and B is not visible in the electron density. Due to the lack of continuity in the electron density between the short helix A and the long helix B of each monomer, the connection between helix A and helix B is ambiguous.

The parallel arrangement of the 2 molecules in a dimer gives rise to a 4-helix bundle at the N-terminal end of the dimer and a long, parallel coiled-coil at the C-terminal end, imparting on the dimer the overall look of a mushroom. We will refer to the segment of the homodimer corresponding to the 4-helix bundle as the cap and the protruding coiled-coil as the stalk (Fig. 4A) and the disordered residues 212 to 226 as the C-terminal tail. The transitions were expressed at higher levels in growing and nitrogen starvation conditions (Fig. 6A). Subcellular fractionation experiments in growing condition showed that the full-length Atg38 was detected in supernatant (S15) and pellet (P15) fractions, whereas all of the deletion proteins were predominantly detected in S15 (Fig. 6B). This suggests that each segment of the C-terminal region is important for association with membranes or larger protein complexes. In nitrogen starvation, we observed similar fractionation patterns except that the capΔ mutant was also present in the P15 fraction, suggesting that the stalk and tail segments are important for association with membranes or larger protein complexes during starvation. In the structure of the Atg38 C-terminal domain homodimer, both the cap and stalk are involved in homodimerization (Fig. 4).
Immunoprecipitation of the C-terminal deletion constructs when expressed in yeast with full-length double protein A-tagged Atg38 (Atg38-ZZ) showed that deletion of the entire C-terminal region (123 to 226Δ) or deletion of the cap and stalk together eliminates dimerization, while deletion of a single element (cap, stalk or tail) still enables some dimer formation (Fig. 6C). This is confirmed by expression of recombinant proteins in E. coli and SEC-MALS of the constructs, which shows that constructs with a single element deleted (capΔ, stalkΔ or tailΔ) remain dimeric, while constructs with 2 or 3 elements deleted are monomeric (Fig. 6D,E). Both the cap and stalk segments are also important for binding to complex I (Atg14-ZZ), as we saw the interactions were decreased for either the C terminusΔ or the capΔ+stalkΔ mutants (Fig. 6F). In summary, the Atg38 C-terminal region is important for PAS localization, homo-dimerization and binding to complex I, as summarized in Fig. 6G.


Discussion

The lipid kinase Vps34 can form 2 stable complex I assemblies

We show that 2 distinct, homogeneous, monodisperse yeast complex I assemblies can be purified. One is a heterotetrameric complex I containing equimolar ratio of the 4 subunits, Vps15-Vps34-Vps30-Atg14. The other is a heteropentameric complex I, with a dimer of the Atg38 subunit binding to the heterotetrameric complex I. Since recombinant complex I can be purified in the absence of Atg38, it does not seem that Atg38 is essential for assembly of the complex. This is further supported by the relatively mild autophagy defect elicited by the atg38Δ mutation compared with mutants lacking the other subunits of the complex I.8 Our results showing that mammalian complex I can be purified either with or without NRBF2 is also consistent with the weak phenotype of the nrbf2Δ−− mice.10 A recent report of a low resolution EM structure of heterotetrameric human complex I without NRBF2 suggests that the complex has some flexibility, but it is not clear what influence NRBF2 might have on this dynamic behavior.13

Our results show that depending on the relative abundance of NRBF2 to complex I, these proteins can make 2 types of assemblies. When complex I is more abundant than NRBF2, the predominant assembly is one NRBF2 dimer linking 2 complex I heterotetramers. When NRBF2 is in excess, it can form an additional assembly in which one NRBF2 dimer is bound to a single complex I. This behavior of NRBF2 contrasts with yeast Atg38 in which the Atg38 homodimer appears to make an asymmetric contact with complex I, without bridging 2 complexes. Although the NRBF2 MIT domain interacts with complex I, the C-terminal domain of NRBF2 is necessary to dimerize complex I. One consequence of NRBF2 forming a dimeric complex may be to increase the affinity of the complex I for membranes.

The low-resolution EM structure of the yeast Vps15-Vps34 subcomplex (Fig. S5) shows that the 2 components formed a stable core, and this assembly may also exist in mammalian cells.18 The EM density of the cross-linked human heterotetrameric and heteropentameric complex I agrees in dimensions with the previously reported V-shaped human tetrameric complex envelope.13

The HDX-MS data for the yeast complex I suggests that the coiled-coil I region in Atg14 (residues 25 to 36) is the main binding site for Atg38. Since Atg14 is the unique component that distinguishes heterotetrameric complex I from complex II, the HDX-MS results are consistent with a specific interaction between Atg38 and yeast complex I. The coiled-coil I in Vps30 was also protected from HDX in the presence of Atg38. Given the dimeric nature of Atg38, it is plausible that one Atg38 molecule binds to Atg14 and another to Vps30 within the same complex I. However, further structural analysis is necessary to reveal the detailed molecular architectures of complex I assemblies. HDX suggests that several regions in complex I are exposed in the presence of Atg38. This suggests that the binding of Atg38 may cause a conformational change in complex I, which may give access to membranes or binding proteins. These dynamic changes may be related to the structural flexibility reported for the human complex I.13

Although our HDX-MS data suggest that Atg38 binds to complex I mainly via the MIT domain, the C-terminal region of Atg38 was also protected from HDX (Fig. 3A). It is not clear whether this protection arises from direct binding to complex I or from conformational changes in Atg38. Nevertheless, the C-terminal region is important for binding to complex I in vivo (Fig. 6F). Higher resolution structural information will be required to understand the roles of the Atg38 C-terminal region upon binding to complex I.

Functions of the C-terminal region of Atg38 during nitrogen starvation

The structure of the C-terminal region from Atg38 clearly shows the role of this domain in forming a parallel homodimer. Unlike its human ortholog NRBF2, Atg38 does not seem to dimerize yeast complex I. This suggests that the Atg38 homodimer is making an inherently asymmetric interaction with complex I. The structure of the homodimeric C-terminal domain of Atg38 shows striking asymmetry. It may be that this asymmetry only arises in the crystalline state of the domain; however, all 3 copies in the asymmetric unit are equivalent asymmetric dimers. Biologically relevant asymmetric dimers are rare, but one function that has been demonstrated for them is adapting a dimer for interaction with a single binding site.19 It may be that the asymmetric Atg38 C-terminal dimer makes an additional interaction with the asymmetric complex I.

In cells, it appears that Atg38 is responsible for incorporating complex I into larger cellular networks on membranes, especially under starvation conditions, as indicated by the ability of Atg38 to mediate complex I association with the P15 pellet in cell fractionation. A previous study suggests that the C-terminal region has additional, unidentified roles in autophagy beyond its role in homodimerization.8 We observed that deleting multiple segments simultaneously in the C-terminal region caused loss of dimerization and delocalization of the mutants from the PAS. However, even single segment deletions in the C-terminal region that remain dimeric caused their displacement from the membrane fraction (Fig. 6B). Our results suggest that the C-terminal domain of Atg38 is involved in interactions with complex I, localization to the PAS and possibly other cellular structures. Understanding how Atg38 and NRBF2 facilitate interactions of complex I with cellular components will have to await structures of these higher-order complexes.

Materials and methods

Constructs

All plasmids are listed Table S1. The full-length ATG38 fragment used in Figs. 5 and 6 was from −997 bp to +737 bp including an intron. It was amplified by PCR using S. cerevisiae genomic DNA as a template and primers yoO568 (aaaggatcgATGGCCAGTATTTACTCTACCTTG) and yoO472 (tttgtgaCTAGTTTTTTGATCTATCCTTCT). The atg38 internal deletion fragments ((capΔ (123 to 181 deleted), stalkΔ (182 to 209 deleted), and capΔ+stalkΔ (123 to 209 deleted)) were generated from the full-length ATG38-carrying plasmid by PCR using appropriate primers. The fragments were ligated.
in the presence of T4 polynucleotide kinase (New England Biolabs, M0201), then further amplified with yoO568 and yoO472. The atg38 C terminusΔ (residues 123 to 226 deleted), stalkΔ, and tailΔ (209 to 226 deleted) fragments were directly obtained by PCR using the full-length ATG38 as a template with appropriate primers. These PCR products were digested with KpnI and SalI, and inserted into pRS416-backbone vectors (pYO769 for 2xGFP encoded by a tandem repeat of EGFP (Clontech, 6085) or pYO484 for 3xFLAG). To generate plasmids expressing human complex I and complex I with NRBF2 (pYO395 and pMO15, respectively), each subunit-coding fragment and EGFP coding fragment were cloned first into pcDNA3.1 (Invitrogen, V79020) or pcDNA4/TO (Invitrogen, V102020) individually. The plasmid carrying VPS15 (PIK3R4) in pcDNA4/TO was then digested with MluI enzyme, and used as a backbone vector. A DNA fragment carrying the CMV/TO promoter-VPS34 (PIK3C3)-BGH polyA site was amplified by PCR using the plasmid carrying VPS34 in pcDNA4/TO as a template and primers opo825 (ctagtcataatactcaagcccgctcagccagcccagctggctc) and opo827 (cgcagatgtagggccagatatagc). The PCR product was inserted into the digested VPS15 vector using an In-Fusion

Figure 5. Effect of Atg38 C-terminal truncations on cellular localization. (A) Schematic representation of C-terminal truncations of Atg38. Genomic DNA fragments containing the ATG38 promoter region (-997 base pairs) and a deletion series of ATG38 were C-terminally fused to an EGFPx2 coding fragment on a CEN plasmid (pRS416). (B) Micrographs of GFP and differential interference contrast (DIC) channels of the Atg38 truncations. The plasmids carrying the truncations described in (A) were transformed into atg38Δ cells. Cells were grown to mid-log phase (OD600D0.8–1.0), then shifted to SD(-N) for 4 h, then subjected to microscopy. Scale bars: 5 μm. (C) Numbers of dots (%) were counted from triplicates of 100 cells/construct ± SD. The graph is a representative of 2 independent experiments. ****, P < 0.0001 compared to full length (FL); NS, Not Significant (P > 0.05) compared to FL.
reaction (Clontech, 639649). The resulting plasmid was again digested with MluI, and used as a backbone vector for the next round of Infusion reaction. The MluI digestion-In-Fusion cycles were repeated until all coding fragments with the promoter and the polyA site were inserted into single vectors. The final arrangement of genes in the pYO395 plasmid expressing human heterotetrameric complex I is ZZ-ATG14-EGFP-BECN1-VPS34-VPS15, and for the pMO15 plasmid expressing human heteropentameric complexes it is ZZ-ATG14-NRBF2-EGFP-BECN1-VPS34-VPS15 (EGFP is used to monitor the efficiency of transfection).

For pYO1025 and pYO1022, a VPS15-2xTEV-ZZ fragment or a ZZ-3xTEV-BECN1 fragment were cloned into a pCAG vector using In-Fusion reactions. Those plasmids were digested with Sall (for pYO1025) or Sall and SpeI (for pYO1022), and used as backbone plasmids for the next rounds of cloning. The

Figure 6. (For figure legend, see page 2139.)
Yeast strains and cell growth

Yeast strains are listed in Table S2. For cell biology, yeast cells carrying plasmids (all in pRS416 backbone) were grown at 30°C in -URA medium (0.67% yeast nitrogen base without amino acids, 0.5% casamino acids and 2% glucose, supplemented with 0.002% adenine sulfate, 0.002% tryptophan, 0.002% tyrosine and 0.002% leucine; modified from Suzuki et al.). To induce nitrogen starvation, the cells were incubated in SD(-N) medium (0.17% yeast nitrogen base without amino acid, without ammonium sulfate and with 2% glucose).

Protein purification

Protein purification procedures for yeast complex I, Vps15-Vps34 dimer, and Vps15-Vps34ΔD731N (KI) dimer were described previously. The Vps15 (WD40Δ)-Vps34ΔD731N (KI) was purified using the same protocol as for the Vps15-Vps34 dimer purification.

Heterotetrameric and heteropentameric human PtdIn3K complexes were purified from HEK293T cells by transient transfection with pY0395 or pMO15. As a transfection agent, polyethyleneimine (PEI) (branched 25,000 Da, Polysciences, 24765) was used at a PEI:DNA ratio of 2:1. Transfection efficiency was assessed by observing the EGFP signal resulting from an additional EGFP expression cassette on the plasmid. Cells were harvested after 48 h.

For purification of both complexes for EM studies, HEK293T pellets were resuspended in lysis buffer (50 mM HEPES, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1 mM EGTA, 0.5 mM CHAPS [Calbiochem, 220201], 8% glycerol, 1 mM DTT, 1X HALT protease inhibitor [Pierce, 78440]). Cells were lysed by sonication on ice for 2 min, followed by centrifugation to remove cell debris. The cleared lysate was added to IgG Sepharose 6 Fast Flow beads (GE Healthcare, 71096092) and agitated by rotation at 4°C. For elution of bound complexes, the ZZ-tag was cleaved by addition of in-house expressed and purified His-TEV protease for 1 h. Fractions containing complex were pooled and concentrated to approximately 0.4 mg/mL. The complex was then stabilized and further purified by Grafix ultracentrifugation. For this purpose, 250 μL protein sample was loaded onto a 3.6 mL 20 to 30% glycerol gradient containing 0.0 to 0.15% glutaraldehyde (25 mM HEPES, pH 8.0, 200 mM NaCl, 1 mM DTT and 20 or 30% [v/v] glycerol). Gradients were centrifuged at 273,000 g in a Beckman SW60Ti rotor (Beckman Coulter, Krefeld, Germany) for 16 h at 4°C. 250 μL fractions were collected from the bottom and analyzed by SDS-PAGE. To identify fractions containing the complex, gradients without crosslinker were analyzed in parallel and these are presented in Fig. 2D.

For purifying human complex I for reconstitution, 5 L of FreeStyle 293-F (ThermoFisher, R79007) cells were grown in a WAVE Bioreactor system (GE Healthcare, CB0202L10-01, Little Chalfont, UK) to a cell density of 1.5 × 10^8 cells/mL. Cells were then transfected with 2.8 mg of pYO1025 and 2.1 mg of pYO1022 using PEI at a PEI:DNA ratio of 2:1. Cells were harvested after 53 h, pelleted (15 min, 3000 g), frozen in liquid nitrogen, and stored at −80°C. To prepare protein, the cells were suspended in 150 mL of lysis buffer (50 mM Tris, pH 8.0, 200 mM NaCl, 1% Triton X-100 [Sigma, X100], 10% glycerol, 0.5 mM tris[2-carboxyethyl]phosphine (TCEP, Soltec Ventures, M115), 2 mM MgCl2, 1x EDTA-free inhibitor tablet (Roche, 05056498001)), and incubated on ice for 30 min. The Insoluble fraction was removed by centrifugation at 18,000 g for 30 min in an SS34 rotor (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The supernatant fraction was incubated with 2 mL of IgG beads for 3.5 h. The beads with supernatant mixture were centrifuged at 1,000 g, and 100 mL of supernatant was removed. The IgG beads were transferred to a gravity flow column, and washed with 150 mL of wash buffer (50 mM Tris, pH 8.0, 200 mM NaCl, 0.1% Triton X-100, 0.5 mM TCEP, 5 mM ATP [Sigma, A2383 ], 50 mM MgCl2, 5 μg/mL RNAseA [Sigma, 83834]) and 150 mL of TEV buffer (50 mM Tris, pH 8.0, 200 mM NaCl, 0.5 mM TCEP). A 10 mL aliquot of TEV buffer and 80 μL of 4.4 mg/mL TEV protease were added, and incubated at 4°C overnight without rotation. After the first TEV elution, 5 mL of TEV buffer was added and eluted again. In total, there was 10 mL overnight elution and 3 times of 5 mL.

Figure 6. (see previous page) Roles of the Atg38 C-terminal domain in dimerization, interaction with complex I and cellular fractionation. (A) All Atg38 C-terminal truncations cause overexpression of the Atg38 constructs. Total cell lysates from growing and nitrogen starvation conditions were subjected to western blotting. The same C-terminal deletion fragments as used in Fig. 5 were C-terminally tagged with 3X FLAG on a CEN plasmid (pRS416). The plasmids were transformed into atg2ΔΔA cells, and grown to mid-log phase (OD600 = 0.8–1.0; Growing), then shifted to SD(-N) for 4 h. Total cell lysates were prepared as described in Materials and Methods. Asterisks indicate protein of interest. Pgk1 expression was used as a loading control. (B) Atg38 C-terminal truncations cause dissociation of the proteins from the P15 pellet. Subcellular fractionation of the same proteins as in (A). Cells were lysed by sonication on ice for 2 min, followed by centrifugation to remove cell debris. The cleared lysate was added to IgG Sepharose 6 Fast Flow beads (GE Healthcare, 17096092) and agitated by rotation at 4°C. For elution of bound complexes, the ZZ-tag was cleaved by addition of in-house expressed and purified His-TEV protease for 1 h. Fractions containing complex were pooled and concentrated to approximately 0.4 mg/mL. The complex was then stabilized and further purified by Grafix ultracentrifugation. For this purpose, 250 μL protein sample was loaded onto a 3.6 mL 20 to 30% glycerol gradient containing 0.0 to 0.15% glutaraldehyde (25 mM HEPES, pH 8.0, 200 mM NaCl, 1 mM DTT and 20 or 30% [v/v] glycerol). Gradients were centrifuged at 273,000 g in a Beckman SW60Ti rotor (Beckman Coulter, Krefeld, Germany) for 16 h at 4°C. 250 μL fractions were collected from the bottom and analyzed by SDS-PAGE. To identify fractions containing the complex, gradients without crosslinker were analyzed in parallel and these are presented in Fig. 2D.

For purifying human complex I for reconstitution, 5 L of FreeStyle 293-F (ThermoFisher, R79007) cells were grown in a WAVE Bioreactor system (GE Healthcare, CB0202L10-01, Little Chalfont, UK) to a cell density of 1.5 × 10^8 cells/mL. Cells were then transfected with 2.8 mg of pYO1025 and 2.1 mg of pYO1022 using PEI at a PEI:DNA ratio of 2:1. Cells were harvested after 53 h, pelleted (15 min, 3000 g), frozen in liquid nitrogen, and stored at −80°C. To prepare protein, the cells were suspended in 150 mL of lysis buffer (50 mM Tris, pH 8.0, 200 mM NaCl, 1% Triton X-100 [Sigma, X100], 10% glycerol, 0.5 mM tris[2-carboxyethyl]phosphine (TCEP, Soltec Ventures, M115), 2 mM MgCl2, 1x EDTA-free inhibitor tablet (Roche, 05056498001)), and incubated on ice for 30 min. The Insoluble fraction was removed by centrifugation at 18,000 g for 30 min in an SS34 rotor (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The supernatant fraction was incubated with 2 mL of IgG beads for 3.5 h. The beads with supernatant mixture were centrifuged at 1,000 g, and 100 mL of supernatant was removed. The IgG beads were transferred to a gravity flow column, and washed with 150 mL of wash buffer (50 mM Tris, pH 8.0, 200 mM NaCl, 0.1% Triton X-100, 0.5 mM TCEP, 5 mM ATP [Sigma, A2383 ], 50 mM MgCl2, 5 μg/mL RNaseA [Sigma, 83834]) and 150 mL of TEV buffer (50 mM Tris, pH 8.0, 200 mM NaCl, 0.5 mM TCEP). A 10 mL aliquot of TEV buffer and 80 μL of 4.4 mg/mL TEV protease were added, and incubated at 4°C overnight without rotation. After the first TEV elution, 5 mL of TEV buffer was added and eluted again. In total, there was 10 mL overnight elution and 3 times of 5 mL.
post-overnight elution. The elution fractions were combined and concentrated using a 100 k concentrator (Millipore, UFC910096) for gel filtration. Gel filtration was done on an S200 10/30 column equilibrated with 20 mM Tris, pH 8.0, 200 mM NaCl, 0.5 mM TCEP. The main peak fractions were pooled and concentrated to 3.2 mg/mL. The proteins were frozen in liquid nitrogen and stored at −80°C. The gel filtration profile is consistent with an excess of BECN1 relative to other subunits of complex I.

Human NRBF2 was purified either as a GST-3C-NRBF2 fusion (pETM-33 backbone, EMBL Protein Expression and Purification Facility) or as a His6-NRBF2 fusion (pOPTH backbone, in-house). For purification of GST-3C-NRBF2, cell pellets were resuspended in lysis buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM DTT), 1x EDTA-free protease inhibitor [Roche, 05056489001]) and lysed by 2 passages through a homogenizer (Avestin EmulsiFlex C3, Avestin, Mannheim, Germany). Cell debris was pelleted and the lysate was incubated with equilibrated glutathione Sepharose 4 Fast Flow resin (GE Healthcare, 17075605) for 2 h at 4°C under agitation. Fractions containing NRBF2 were pooled and 3C cleavage was performed overnight at 4°C. The cleaved protein was concentrated to 2 mg/mL with a 10-kDa cut-off spin concentrator (Millipore, UFC201024) and further purified by gel filtration on a Superdex 200 10/300 GL column (GE Healthcare, 17517501) in gel filtration buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM DTT). For the purification of the His6-NRBF2 full-length and His6-NRBF2-MIT domain (residues 1 to 89), cells were lysed in 25 mM Tris-HCl, pH 7.5, 0.3 M NaCl, 2 mM β-mercaptoethanol, 0.05 μg/mL universal nuclese (Pierce, 88702), 0.5 mg/mL lysozyme (Sigma, L6876) and 10 mM imidazole (Sigma, S6749) by sonication for 10 min. After ultracentrifugation, supernatant fractions were filtered and loaded on a His-Trap FF 5 mL column (GE Healthcare, 17-5255-01) equilibrated in buffer A (20 mM Tris-HCl, pH 7.5, 0.3 M NaCl, 1 mM TCEP, 10 mM imidazole), washed with the same buffer and eluted with a gradient of 10 to 300 mM imidazole in 20 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 1 mM TCEP. The peak fractions were pooled, concentrated and gel filtered on a Superdex 75 16/60 column equilibrated in 20 mM Tris-HCl, pH 7.5, 0.1 M NaCl, 0.5 mM TCEP. Peak fractions were pooled, concentrated, frozen in liquid N2 and stored at −80°C.

**Protein purification of Atg38**

*S. cerevisiae* Atg38 constructs (full-length, N-terminal MIT domain (residues 1 to 78), the C-terminal fragment (residues 87 to 226) and various C-terminal truncation variants (C terminusΔ = residues 123 to 226 deleted, capΔ = 123 to 181 deleted, stalkΔ = 182 to 209 deleted, capΔ + stalkΔ = 123 to 209 deleted, stalkΔ + tailΔ = 182 to 226 deleted, tailΔ = 210 to 226 deleted) were expressed in E. coli. Cells were grown at 37°C to OD600 = 1.0, induced with 0.3 mM IPTG (Formedium, IPTG100) and incubated for a further 4 to 4.5 h at 37°C. Cells were resuspended in lysis buffer (25 mM Tris-HCl, pH 7.5, 0.2 M NaCl, 1 mM TCEP, 0.05 μg/mL Universal nuclese [Pierce, 88702], 0.5 mg/mL lysozyme and 1 mM PEFA [Melford, MB2003]) and sonicated for 6 min. After ultracentrifugation at 142,000 g for 45 min in a Ti45 rotor (Beckman Coulter, Krefeld, Germany), supernatant fractions were filtered and loaded on Glutathione Sepharose 4B resin (GE Healthcare, 17075605) equilibrated in 20 mM Tris-HCl, pH 7.5, 0.2 M NaCl, 2 mM DTT, washed extensively with the same buffer and either eluted with 10 mM glutathione, 50 mM Tris-HCl, pH 8.5, or cut with TEV protease, as needed. The full-length and N-terminal fragment of Atg38 were further purified on HiTrap Q column equilibrated in 20 mM Tris-HCl, pH 8.8, 1 mM TCEP and eluted with a NaCl gradient in the same buffer. After SDS-PAGE analysis, the relevant fractions were pooled and concentrated in Amicon Ultra 10-kDa cut-off concentrator (Millipore, UFC901024). All constructs were run on a S75 16/60 column equilibrated in 20 mM Tris-HCl, pH 8.8, 150 mM NaCl, 1 mM TCEP.

**Western blotting**

For the preparation of total cell lysates in Fig. 6A, about 10 OD600 units of cells at midlog phase (OD600 = 0.8 to 1.0) were harvested in 1.5 mL tubes, flash frozen in liquid nitrogen, and stored at −80°C. The cells were treated using a cell wall loosening procedure (2 M LiAc on ice for 3 min followed by 0.4 M NaOH on ice for 3 min),21 and disrupted in 50 mM Tris (pH 8.0), 1% SDS, 8 M urea (WVR, 28877), 2 mM DTT, 5 mM EDTA with glass beads at 3,000 rpm for 30 sec with PowerLyzer homogenizer (MO BIO Laboratories, 13155, Carlsbad, California, USA) at 4°C. One volume of 4X sample buffer was added to 3 volumes of the lysates and loaded onto the gel. Proteins were detected using a mouse anti-Pgk1 antibody (Invitrogen, 459250) with anti-mouse-IgG HRP (Sigma, A9917), or an anti-Flag M2-HRP (Sigma, A8592). For detecting the His-tagged human NRBF2 MIT domain, Penta-His HRP conjugate Kit (Qiagen, 34660) was used with BenchMark (Invitrogen, 10747012) as a marker.

**Subcellular fractionation**

Subcellular fractionation was performed using a modified version of a described procedure.22 Approximately 50 OD600 units of cells at midlog phase both in a standard growing condition and in nitrogen starvation condition were harvested, flash frozen in 2 mL tubes in liquid nitrogen, and stored at −80°C. Cells were suspended in 200 μL of lysis buffer (50 mM Tris, pH 8.0, 50 mM NaCl, 1 mM DTT, 0.5 mM PMSF, EDTA-free protease inhibitor tablet [Roche, 05056489001]) and glass beads. Cells were disrupted with a FastPrep–24 homogenizer (MP Biomedicals, 116004500, Santa Ana, California, USA) at 6.5 intensity for 45 sec. Cell debris, nucleus, and glass beads were removed by centrifuging at 1,000 g for 1 min. Supernatant fractions were transferred to new 1.5 mL tubes, and again centrifuged at 1,000 g for 5 min. The supernatant fractions from this spin represent the total fractions (T), and 150 μL of total was transferred to fresh 1.5 mL tubes and further spun at 15,000 g for 10 min to obtain S15 (supernatant) and P15 (pellet) fractions. P15 pellets were resuspended in 1% SDS, 8 M urea, 100 mM DTT.

**Immunoprecipitation**

Cells were grown in 100 mL of -URA medium to midlog phase, then shifted to SD(-N) for 4 h at 30°C, harvested in 2 mL tubes,
flash-frozen in liquid nitrogen, and stored at $-80^\circ$C. Cells were suspended in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl for Atg14-ZZ or 200 mM NaCl Atg38-ZZ, 2 mM $\beta$-mercaptoethanol, 12.5% glycerol, 1% Triton X-100, 0.5 mM PMSF, EDTA-free inhibitor tablet [Roche, 05056489001]) and disrupted with glass beads using a FastPrep-24 at 6.5 intensity for 45 sec. Cell debris and glass beads were removed by spinning at 20,000 g for 1 min, supernatant fractions were transferred to new 1.5 mL tubes, and centrifuged at 20,000 g for 2 min. Supernatant fractions were transferred to new 1.5 mL tubes, and 15 $\mu$L of anti-Flag M2 agarose beads (Sigma, A2220) were added and rotated at 4°C for 2 h. The beads were washed 5 times with 1 mL of lysis buffer, and resuspended in SDS sample buffer. Both lysates and IP fractions were loaded on gels without boiling. Proteins were detected with an anti-Flag M2-HRP (Sigma, A8592), or a peroxidase anti-peroxidase complex (PAP, Sigma, P1291) antibody.

**HDX measurements of deuterium incorporation**

Protein samples (10 $\mu$L of 2.5 $\mu$M protein in 20 mM Tris, pH 8.0, 50 mM NaCl, 2 mM TCEP) were mixed rapidly with 35 $\mu$L of D$_2$O Buffer (96.6% D$_2$O, 20 mM Tris, pH 8.0, 50 mM NaCl, 2 mM TCEP), producing a sample with a final concentration of 75% D$_2$O. Four time points of exchange (3 sec, 30 sec, 300 sec and 3000 sec, at $23^\circ$C) were conducted, and the reactions were quenched with 20 $\mu$L of Quench Buffer (8.4% formic acid, 5 M guanidine-HCl), and immediately frozen in liquid nitrogen. Samples were stored at $-80^\circ$C until mass spectrometry analysis.

Rapidly thawed samples were immediately injected onto an ultra performance liquid chromatography (UPLC) system described below immersed in ice. In order to digest the deuterated protein, the sample was passed through 2 immobilized peptin Porosyme columns (Applied Biosystems, 2-3131-00) at 150 $\mu$L/min for 3 min and the peptides were collected over a VanGuard C18 pre-column trap (Waters, 186003975). Peptic peptides were eluted from the trap by switching the flow to an in-line C18 UPLC column (Acquity 1.7 $\mu$m particle, 100 mm x 1 mm, Waters, 186002346). Peptic peptides were eluted from the column using a 20 min 5 to 45% gradient of buffer A (0.1% formic acid) and buffer B (100% acetonitrile), followed by a 4 min wash with 76% buffer B. Peptides eluted from the column were injected into a Xevo QTOF (Waters Corporation, Milford, MA, USA), acquiring for 30 min over an m/z range of 350 to 1500 using an electrospray ionization (ESI) source operated at a capillary temperature of 225°C, and a spray voltage of 3.5 kV.

**Peptide identification**

Peptide identification was conducted by running tandem MS/MS experiments with a nondeuterated sample digested as above but with an extended, 60-min gradient over the UPLC column, rather than 20 min. An MS/MS was then conducted with a 20-min gradient, in order to correct the retention times for the identification runs done with the longer gradient. The MS tolerance was set to 15 ppm with an MS/MS tolerance of 0.2 Da. The resulting MS/MS datasets were analyzed using the Mascot search program within the Proteome Discoverer software package (Thermo Scientific). Peptides with a Mascot score less than 10 were excluded from further analysis. The remaining peptides were examined with HD-Examiner software (Sierra Analytics). The centroid value for each nondeuterated peptide was manually confirmed by searching the protein sample’s MS scan to check for the correct m/z state, the presence of any overlapping peptides, and the correct retention time (any peptides failing these criteria were excluded from further analysis at the point).

**Mass analysis of peptide centroids**

Validated nondeuterated peptides were subsequently analyzed for their deuterium incorporation (Figs. S6 to S16). Some overlapping peptides appeared due to a shift in m/z seen upon incorporation of deuterium and they were discarded from the data set. All peptides were once more validated for correct m/z and retention time. The deuterium levels referred to in the figures and the text are the relative levels of deuterium, as no fully deuterated sample was obtained. A mathematical correction was applied to compensate for the differences in the level of the deuterium in the exchange buffer (75%). The average error between replicate peptides was $\leq 0.5$ Da. For our analysis, we considered as significant changes that were greater than 0.9 Da for both observations.

**Measurement of intact mass of Atg38 C terminus.**

A 65 $\mu$L sample of 1.5 mg/ml of Atg38 C terminus was precipitated using methanol and chloroform, sedimented, and resuspended in 100 $\mu$L of a 50% methanol and 1% formic acid solution. This protein solution was then injected at a rate of 10 $\mu$L/min onto a Micromass LCT TOF (Waters Corporation, Milford, MA, USA), fitted with an ESI source, run with a sample cone voltage of 40 V, a capillary voltage of 2800 V, and a desolvation temperature of 80°C. The intact, denatured mass of the protein was determined using Micromass Maximum Entropy (MaxEnt) deconvolution software.

**Size exclusion chromatography coupled to multiangle light scattering (SEC-MALS)**

The molecular masses in solution of yeast complex I, yeast complex I+Atg38, Atg38, human complex I, human complex I+NRBF2, NRBF2, and NRBF2 MIT domain were determined by SEC-MALS measurements using a Wyatt Heleos II 18 angle light scattering instrument coupled with a Wyatt Optilab rEX online refractive index detector (Wyatt, Goleta, California, USA). The molecular mass of NRBF2 in Fig. 2B was analyzed using a modular triple detector array (Viscotek TDA 305, Malvern Instruments Ltd., Malvern, UK) for online right-angle light scattering (RALS), refractive index and UV-vis determination calibrated using bovine serum albumin narrow standard. The protein samples were resolved on a S200 10/30, S75 10/30 (GE Healthcare, 17-1047-01), Superose 6 10/30 (GE Healthcare, 17-0537-01) or Superdex 200 10/300 increase (for NRBF2 in Fig. 2B) analytical gel filtration column (GE Healthcare, 28990944) running at 0.5 mL/min. The gel filtration buffers were 20 mM Tris, pH 8.8, 150 mM NaCl, 1 mM TCEP for complex I and complex I+Atg38, and 20 mM Tris, pH 7.9, 300 mM NaCl, 1 mM TCEP for Atg38, 20 mM Tris, pH 8.0, 200 mM...
NaCl, 0.5 mM TCEP for human complex I, human complex I+NRBF2, human complex I+NRBF2 MIT domain, NRBF2, NRBF2 MIT domain, and 50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM DTT for NRBF2 in Fig. 2B. The protein concentrations were determined from the excess differential refractive index based on 0.186 RI increment for 1 g/ml protein solution. The concentration and the observed scattered intensity at each point in the chromatograms were used to calculate the absolute molecular mass using ASTRa 6 software (Wyatt) or Omniseq (Malvern) software.

**GST affinity isolation assays**

The purified yeast complex I (at a final concentration of 1.78 μM) was mixed with 10-fold excess of GST, GST-Atg38 (1 to 226), GST-Atg38 (1 to 78), or GST-Atg38 (87 to 226). Initially, GST or GST fusion proteins were incubated on ice for 30 min with 20 μL of glutathione Sepharose 4 Fast Flow resin, which had been equilibrated with reaction buffer (50 mM Tris, pH 8.8, 150 mM NaCl, 1 mM TCEP). The beads were washed once with 1 mL of reaction buffer, then the volume was adjusted to 90 μL. A 10 μL aliquot of 17.8 μM complex I was added to the beads, which were then incubated on ice for 90 min. The reactions were transferred to Poly-Prep Chromatography Columns (Bio-Rad, 7311550), and washed once with 1 mL of reaction buffer, then the volume was adjusted to 90 μL, and 90 μL of reaction buffer was added to the resin to represent the bound fractions. For analysis, samples consisting of either 1:10 dilution of the input or the bound fractions were loaded on a SDS-PAGE gel. After electrophoresis, the gel was stained with InstantBlue (Expedeon, ISB1L).

**Reconstitution of human and yeast complex I with NRBF2/Atg38**

Purified human complex I and purified human NRBF2 or NRBF2 MIT domain were mixed in gel filtration buffer (20 mM Tris, pH 8.0, 200 mM NaCl, 0.5 mM TCEP), incubated on ice for 30 min and loaded on a Superose 6 10/30 column. For 6:1 molar ratio of complex I to NRBF2 (full-length or MIT domain), 8.8 μM complex I was mixed with 1.47 μM NRBF2 in a 110 μL reaction and for 1:6 molar ratio of complex I to NRBF2, 8.8 μM complex I was mixed with 52.8 μM NRBF2 in a 110-μL reaction. For yeast complex reconstitution, yeast complex I and Atg38 were mixed in gel filtration buffer (20 mM Tris, pH 8.8, 150 mM NaCl, 0.5 mM TCEP), incubated on ice for 30 min and loaded on an S200 10/30 column. For 6:1 molar ratio of complex I to Atg38, 8.6 μM complex I was mixed with 1.4 μM Atg38 in a 120 μL reaction and for 1:6 molar ratio of complex I to Atg38, 8.6 μM complex I was mixed with 51.7 μM Atg38 in a 120 μL reaction. Fractions from gel-filtration runs were analyzed by SDS-PAGE and gels were stained with InstantBlue.

**Electron microscopy and image processing**

A 4-μL aliquot of diluted full-length yeast Vps15-Vps34_D731N (KI) or Vps15 (WD40Δ) (1 to 981)-Vps34_D731N (KI) was applied to glow-discharged grids (Plano 300 mesh or Quantifoil R2/2) coated with a continuous carbon layer. After adsorption for 30 to 120 sec, the sample was stained by the droplet method using 2% (w/v) uranyl acetate.

For initial model reconstruction of the binary ScVps15 (WD40Δ)-Vps34 complex, 27 micrograph tilt-pairs of the Vps15Δ WD40-Vps34 complex were recorded at 0° and 55° stage tilt with a US4000 Gatan CCD camera (Pleasanton, California, USA) using an FEI Titan Krios (Hillsboro, Oregon, USA) operated at 120 kV. Micrographs were recorded at an underfocus between 1.0 and 1.5 μm at a magnification of 47,000 corresponding to a pixel size of 1.78 Å. In order to generate the initial structure of the truncated complex, we performed random-conical tilt (RCT) reconstruction. A total of 4,221 particle tilt pairs were windowed using e2RCTXbox, and low-pass filtered to 20 Å. Using the unfiltered particle set, class averages were computed using EMAN2, each containing at least 60 members. Together with the tilted particle set, initial models were reconstructed for each class by EMAN2. After CTF correction by phase flipping, with additional unfiltered particles, a total of 6,891 particles were used for 3D structure refinement in EMAN2, using the RCT reconstructions low-pass filtered to 50 Å as initial models.

Images of the binary yeast Vps15-Vps34 complex were acquired on an FEI Polara microscope (Hillsboro, Oregon, USA) operated at 100 kV at a nominal underfocus of 1.0 μm and a magnification of 59,000 corresponding to a pixel size 1.91 Å recorded using a US4000 Gatan CCD camera. From a total of 670 micrographs (binned by a factor of 2), 14,172 particles were windowed semianually in E2BOXER with a box size of 430 × 430 Å. The resulting particle stack was subjected to CTF estimation in EMAN2 and subsequently CTF corrected by phase flipping, followed by a band-pass filter operation from 20 Å to 200 Å. Reference-free 2D classification was performed by iterative multivariate statistical analysis (MSA) and alignment alternating between IMAGIC (Image Science Software GmbH, Berlin, Germany) and SPIDER software packages.

Several cycles of classification and alignment were performed until convergence. After each iteration, the class averages were subjected to manual selection of nonredundant and detailed class averages, followed by alignment and masking, in order to prepare them as references for the following MSA iteration. Prior to refinement, the initial models from the RCT reconstruction and the refined truncated complex were low-pass filtered to 50 Å and 80 Å, respectively. Projection matching-based 3D structure refinement was performed with the entire particle set using SPIDER. Different initial models, obtained either from RCT reconstruction or the refined yeast Vps15 (WD40Δ)-Vps34 data set, converged to very similar refined 3D volumes of the Vps15-Vps34 complex. The resolution of the converging structure was determined at 28 Å from the Fourier Shell Correlation (0.5 cutoff criterion) between 2 independent half-set reconstructions.

GraphFix fractions of the human heterotetrameric and heteropentameric complexes were applied to carbon-coated grids and stained with 0.75% (w/v) uranyl formate as described above. Micrographs were acquired on an FEI Polara microscope operated at 100 kV at a magnification of 23,000 (5.1 A/pixel) for the heterotetrameric complex and 31,000 (3.82 A/pixel) for the heteropentameric complex with a US4000 CCD camera at an
underfocus of 1 μm. A total of 372 micrographs were used to semiautomatically window 17,716 particles of the tetrameric complex, whereas for the pentameric complex 930 micrographs were acquired, of which 20,000 particles were semiautomatically boxed. Both particle sets were band-pass filtered from 25 to 400 Å and normalized, followed by iterative 2D classification as described above. Due to the observed structural heterogeneity and the limited particle set size, 3D structure refinement did not converge satisfactorily.

**Crystallization of Atg38**

Crystals were obtained using the full-length Atg38 protein that was subjected to limited proteolysis with subtilisin and set up for crystallization without further purification: Atg38 (300 μL at 16 mg/mL in gel-filtration buffer containing 20 mM Tris-HCl, pH 8.8, 150 mM NaCl, 1 mM TCEP) was mixed with subtilisin (3 μL at 1 mg/mL; ProteAce kit [Hampton Research, HR2-429]), incubated for 10 h at 4°C and set up for crystallization without further purification. About 1800 crystallization conditions were screened using in-house nanoliter crystallization robotics29 in 96-well MRC plates, by mixing 100 nL of protein with 100 nL of reservoir solution. The initial crystals were obtained from a Pi-minimal screen condition 3, containing 2 M ammonium nitrate, 0.15 M L-malate, pH 5.0 and 0.160 M magnesium sulfate (Jena Bioscience, CS-127).30 Optimal crystals were obtained from grids setup with a screen optimizer Dragonfly (TTP Labtech, Melbourne, UK), from a condition containing 1.97 M ammonium nitrate, 0.15 M (D/L) malate, pH 5.0 and 0.136 M magnesium sulfate. Ethylene glycol (2 μL of 30% stock) was added to the drop prior to crystal fishing. Selenomethionine-labeled crystals were obtained in similar conditions using standard protocols.

**Solving the Atg38 structure**

Native and anomalous datasets were collected on beamline ID29 at the European Synchrotron Radiation Facility, diffracting respectively at 2.2 Å and 2.5 Å. Data sets were processed with XDS,31 and the phasing procedure was carried on peak and inflection point dataset using the PHENIX AutoSol program.32 The model obtained from experimental phases was refined against our best native data set at 2.2 Å using the PHENIX suite.

**Statistical analyses**

All data were obtained from at least 3 independent experiments, and the results were presented as mean ± SD. Data were analyzed by one-way analysis of variance (ANOVA) followed by a multiple comparisons test (P<0.05), using Prism 7 for Mac OSX (GraphPad Software, Inc.).

**Accession numbers**

The EM density of the yeast Vps15-34 complex and the corresponding PDB coordinates have been deposited to the Electron Microscopy Data Bank and Protein Data Bank with accession codes EMD-8235 and PDB-5KC2. The coordinates and diffraction data for the Atg38 C-terminal domain have been deposited to the Protein Data Bank, with accession code 5KC1.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| ATG | autophagy related |
| BECN1 | Beclin 1, autophagy related |
| EGFP | enhanced green fluorescent protein |
| EM | electron microscopy |
| GraFix | gradient fixation |
| GST | glutathione S-transferase |
| HDX-MS | hydrogen-deuterium exchange mass spectrometry |
| HEK293 | human embryonic kidney293 |
| KI | kinase inactive |
| MIT | microtubule-interacting and targeting |
| NRBF2 | nuclear receptor-binding factor 2 |
| PAS | phagophore assembly site |
| PCR | polymerase chain reaction |
| PEI | polyethyleneimine |
| PIK3C3 | phosphatidylinositol 3-kinase catalytic subunit type 3, VPS34 |
| PIK3R4 | phosphoinositide 3-kinase regulatory subunit 4, VPS15 |
| PtdIns3K | phosphatidylinositol 3-kinase |
| PtdIns3P | phosphatidylinositol 3-phosphate |
| SDS-PAGE | sodium dodecyl sulfate polyacrylamide gel electrophoresis |
| SEC-MALS | size exclusion chromatography coupled with multi-angle light scattering |
| TCEP | tris(2-carboxyethyl)phosphine |
| TEV | tobacco etch virus protease |
| UVRAG | UV radiation resistance-associated gene protein |
| Vps | vacuolar protein sorting |
| WD40 | tryptophan aspartate containing repeat of about 40 residues |
| WT | wild type |

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank Sarah Maslen, Mark Skehel and Sew-Yeu Peak-Chew for help with mass spectrometry, Ksenia Rostislavleva for help with X-ray data collection and protein purification and Pat Edwards for advice on mammalian cell expression. We thank Wim Hagen for assistance with EM data collection. We thank Daniele De Sanctis for assistance with ESRF beamline ID29.

**Funding**

LZ was supported by MRC and Cambridge Overseas trust. M.K. and A.J.J. were supported by EMBL Interdisciplinary Postdoc (EIPOD) fellowships under Marie Curie Actions (PCOFUND-GA-2008-229597) and a Marie-Skłodowska-Curie Intra-European fellowship (PIEF-GA-2012-331285 to A.J.J.). JEB was supported by a grant from the British Heart Foundation (PG11/109/29247). This work was funded by the BBSRC (BB/K019155/1 to NTK and RLW) and the Medical Research Council (MC_U105184308 to RLW).
References

[1] Raiborg C, Schink KO, Stenmark H. Class III phosphatidylinositol 3-kinase and its catalytic product PI(3)P in regulation of endocytic membrane traffic. FEBS J 2013; 280:2730-42; PMID:23289851; http://dx.doi.org/10.1111/febs.12116

[2] Thoresen SB, Pedersen NM, Liestøl K, Stenmark H. A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic. Exp Cell Res 2010; 316:3368-78; PMID:20643123; http://dx.doi.org/10.1016/j.yexcr.2010.07.008

[3] Simonsen A, Tooze S. Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes. J Cell Biol 2009; 186:773-82; PMID:19797076; http://dx.doi.org/10.1083/jcb.200907014

[4] Itakura E, Mizushima N. Characterization of autophagosome formation site by a hierarchical analysis of mammalian Atg proteins. Autophagy 2010; 6:764-76; PMID:20639694; http://dx.doi.org/10.4161/aut.6.6.12709

[5] Suzuki K, Kirisako T, Kamada Y, Mizushima N, Noda T, Ohsumi Y. The pre-autophagosomal structure organized by concerted functions of APG genes is essential for autophagosome formation. EMBO J 2001; 20:5971-81; PMID:11689437; http://dx.doi.org/10.1093/emboj/20.21.5971

[6] Kihara A, Noda T, Ishihara N, Ohsumi Y. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carbonylation of Y sorting in Saccharomyces cerevisiae. J Cell Biol 2001; 152:519-30; PMID:11157979; http://dx.doi.org/10.1083/jcb.152.3.519

[7] Rostislavleva K, Soler N, Ohashi Y, Zhang L, Pardon E, Burke JE, Rostislavleva K, Soler N, Ohashi Y, Zhang L, Pardon E, Burke JE, Kihara A, Noda T, Ishihara N, Ohsumi Y. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxyptidylase Y sorting in Saccharomyces cerevisiae. J Cell Biol 2001; 152:519-30; PMID:11157979; http://dx.doi.org/10.1083/jcb.152.3.519

[8] Araki Y, Ku WC, Akioka M, May AI, Hayashi Y, Arisaka F, Ishihama Y, Ohsumi Y. Atg38 is required for autophagy-specific phosphatidylinositol 3-kinase complex integrity. J Cell Biol 2013; 203:299-313; PMID:24165940; http://dx.doi.org/10.1083/jcb.201304123

[9] Cao Y, Wang Y, Abi Saab WF, Yang F, Pessin JE, Backer JM. NRBF2 regulates macroautophagy as a component of Vps34 Complex I. Biochem J 2014; 461:315-22; PMID:24785657; http://dx.doi.org/10.1042/BJ20140151

[10] Lu J, He L, Behrends C, Araki M, Araki K, Jun Wang Q, Cao Y, Wang Y, Abi Saab WF, Yang F, Pessin JE, Backer JM. NRBF2 regulates macroautophagy as a component of Vps34 Complex I. Biochem J 2014; 461:315-22; PMID:24785657; http://dx.doi.org/10.1042/BJ20140151

[11] Kastner B, Fischer N, Golas MM, Sander B, Dube P, Boehringer D, Hartmuth K, Deckert J, Hauer F, Wolf E, et al. GraFix: sample preparation for single-particle electron cryomicroscopy. Nat Meth 2008; 5:53-5; http://dx.doi.org/10.1038/nmeth1139

[12] Zhang T, Lei J, Yang H, Xu K, Wang R, Zhang Z. An improved method for whole protein extraction from yeast Saccharomyces cerevisiae. Yeast 2011; 28:795-8; PMID:21927073; http://dx.doi.org/10.1007/s12195

[13] van Heel M, Harauz G, Orlova EV, Schmidt R, Schatz M. A new generation of the IMAGIC image processing system. J Struct Biol 1996; 116:17-24; PMID:8742718; http://dx.doi.org/10.1006/jsbi.1996.0017

[14] Frank J, Radermacher M, Akioka M, May AI, Hayashi Y, Arisaka F, Ishihama Y, Ohsumi Y. Atg38 is required for autophagy-specific phosphatidylinositol 3-kinase complex integrity. J Cell Biol 2013; 203:299-313; PMID:24165940; http://dx.doi.org/10.1083/jcb.201304123

[15] Stock D, Perisic O, Lowe J. Robotic nanolitre protein crystallisation for single particle reconstructions. J Struct Biol 2009; 166:77-86; PMID:19199175; http://dx.doi.org/10.1016/j.jsb.2006.05.009

[16] Mindell JA, Grigorieff N. Accurate determination of local defocus and specimen tilt in electron microscopy. J Struct Biol 2003; 142:334-47; PMID:12791660; http://dx.doi.org/10.1016/S1047-8477(03)00069-8

[17] van Heel M, Harauz G, Orlova EV, Schmidt R, Schatz M. A new generation of the IMAGIC image processing system. J Struct Biol 1996; 116:17-24; PMID:8742718; http://dx.doi.org/10.1006/jsbi.1996.0004

[18] Frank J, Radermacher M, Penzcek P, Zhu J, Li Y, Ladjadj M, Leith A. SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol 1996; 116:190-9; PMID:8742743; http://dx.doi.org/10.1006/jsbi.1996.0030

[19] Stock D, Perisic O, Lowe J. Robotic nanolitre protein crystallisation at the MRC Laboratory of Molecular Biology. Prog Biophys Mol Biol 2005; 88:311-27; PMID:15652276; http://dx.doi.org/10.1016/j.pbiomolbio.2004.07.009

[20] Gorice F, Palmer CM, Lebon G, Warne T. Pi sampling: a methodical flexible approach to initial macromolecular crystallization. Acta Crystallogr D Biol Crystallogr 2010; 66:213-21; PMID:20124702; http://dx.doi.org/10.1107/S0907449909052925